Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
about
Flexibility of the flap in the active site of BACE1 as revealed by crystal structures and molecular dynamics simulationsBACE1 (β-secretase) inhibitors for the treatment of Alzheimer's diseaseDeveloping β-secretase inhibitors for treatment of Alzheimer's disease.Fragment informatics and computational fragment-based drug design: an overview and update.De novo design: balancing novelty and confined chemical space.The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.N-(3-(2-amino-6,6-difluoro-4,4a,5,6,7,7a-hexahydro-cyclopenta[e][1,3]oxazin-4-yl)-phenyl)-amides as BACE1 inhibitors: a patent evaluation of WO2013041499.Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis.Protective effects of a piperazine derivative [N-{4-[4-(2-methoxy-phenyl)-piperazin-1-yl]-phenyl} carbamic acid ethyl ester] against aluminium-induced neurotoxicity: insights from in silico and in vivo studies.Effect of sampling on BACE-1 ligands binding free energy predictions via MM-PBSA calculations.Design, synthesis, and X-ray structural studies of BACE-1 inhibitors containing substituted 2-oxopiperazines as P1'-P2' ligands.Chemometric design to explore pharmacophore features of BACE inhibitors for controlling Alzheimer's disease.
P2860
Q27676370-17C4B0B1-8D9F-4DCC-9AFF-160016424853Q34156758-E4CFE4EE-FE2B-459D-B8FF-C6BC2C73DB7AQ35746998-63797C25-C942-40F1-A3C8-CCE6F59C8E99Q37995087-A98DD895-E0CB-4784-BDBE-746A99B429ABQ38029143-59489A7B-F3CB-4899-AC93-2365AE694E90Q38127826-3CFE3A39-F031-4968-9090-81ADDDC0B12CQ38161935-0CC273ED-E597-4C5A-B0E8-C91A868B14DDQ38300892-D21F3FE9-9DF5-4CCA-A035-7F48177713AAQ47788147-B6890256-C8F8-488A-9A24-B7FE4A214E60Q48022145-AB7866C1-4D0C-40E1-B78E-FBAAE1BFAA23Q51044301-B7D2DF52-9FA9-4F21-BF0A-13A1075FB16EQ53000363-941FAF64-DD83-4098-BCA4-4C035F5058BB
P2860
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@ast
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@en
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@nl
type
label
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@ast
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@en
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@nl
prefLabel
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@ast
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@en
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@nl
P2093
P50
P1476
Piperazine sulfonamide BACE1 inhibitors: design, synthesis, and in vivo characterization
@en
P2093
Andrew Stamford
Carolyn Carrol
Dawit Tadesse
Eric Parker
Guoqing Li
Jared Cumming
Johannes Voigt
Kurt Saionz
Lili Zhang
Lynne Ozgur
P304
P356
10.1016/J.BMCL.2010.03.050
P407
P577
2010-05-01T00:00:00Z